A pulmonalis hypertonia aktuális kérdései

Translated title of the contribution: Current issues in pulmonary hypertension

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pulmonary hypertension is a multietiological disease. Other forms have to be excluded to establish this diagnosis. Pulmonary hypertension is classified into five categories. One of these forms is pulmonary arterial hypertension with special treatment options. There are three main pathophysiological pathways and corresponding treatment includes the administration phosphodiesterase-5 inhibitors, endothelin receptor antagonists and prostacyclin derivates. Novel therapeutic options are under development. Patients with pulmonary hypertension need regular care and their treatment has to be conducted in specified centres.

Original languageHungarian
Pages (from-to)603-606
Number of pages4
JournalOrvosi Hetilap
Volume153
Issue number16
DOIs
Publication statusPublished - Apr 1 2012

Fingerprint

Pulmonary Hypertension
Phosphodiesterase 5 Inhibitors
Epoprostenol
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A pulmonalis hypertonia aktuális kérdései. / Forster, T.

In: Orvosi Hetilap, Vol. 153, No. 16, 01.04.2012, p. 603-606.

Research output: Contribution to journalArticle

Forster, T. / A pulmonalis hypertonia aktuális kérdései. In: Orvosi Hetilap. 2012 ; Vol. 153, No. 16. pp. 603-606.
@article{57841d9add0b4215ac96c5b70744eb8a,
title = "A pulmonalis hypertonia aktu{\'a}lis k{\'e}rd{\'e}sei",
abstract = "Pulmonary hypertension is a multietiological disease. Other forms have to be excluded to establish this diagnosis. Pulmonary hypertension is classified into five categories. One of these forms is pulmonary arterial hypertension with special treatment options. There are three main pathophysiological pathways and corresponding treatment includes the administration phosphodiesterase-5 inhibitors, endothelin receptor antagonists and prostacyclin derivates. Novel therapeutic options are under development. Patients with pulmonary hypertension need regular care and their treatment has to be conducted in specified centres.",
keywords = "endothelin receptor antagonist, phosphodiesterase-5 inhibitor, prostacyclin derivate, pulmonary hypertension",
author = "T. Forster",
year = "2012",
month = "4",
day = "1",
doi = "10.1556/OH.2012.29358",
language = "Hungarian",
volume = "153",
pages = "603--606",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "16",

}

TY - JOUR

T1 - A pulmonalis hypertonia aktuális kérdései

AU - Forster, T.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Pulmonary hypertension is a multietiological disease. Other forms have to be excluded to establish this diagnosis. Pulmonary hypertension is classified into five categories. One of these forms is pulmonary arterial hypertension with special treatment options. There are three main pathophysiological pathways and corresponding treatment includes the administration phosphodiesterase-5 inhibitors, endothelin receptor antagonists and prostacyclin derivates. Novel therapeutic options are under development. Patients with pulmonary hypertension need regular care and their treatment has to be conducted in specified centres.

AB - Pulmonary hypertension is a multietiological disease. Other forms have to be excluded to establish this diagnosis. Pulmonary hypertension is classified into five categories. One of these forms is pulmonary arterial hypertension with special treatment options. There are three main pathophysiological pathways and corresponding treatment includes the administration phosphodiesterase-5 inhibitors, endothelin receptor antagonists and prostacyclin derivates. Novel therapeutic options are under development. Patients with pulmonary hypertension need regular care and their treatment has to be conducted in specified centres.

KW - endothelin receptor antagonist

KW - phosphodiesterase-5 inhibitor

KW - prostacyclin derivate

KW - pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=84859992577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859992577&partnerID=8YFLogxK

U2 - 10.1556/OH.2012.29358

DO - 10.1556/OH.2012.29358

M3 - Article

C2 - 22510315

AN - SCOPUS:84859992577

VL - 153

SP - 603

EP - 606

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 16

ER -